Chemotherapy for advanced testicular cancer

Abstract

Testis cancer has become one of the most curable of all solid malignancies. More than 95% of patients should be cured with appropriate treatment and should have few long-term treatment-related side effects. Current chemotherapy for advanced testis cancer has resulted from an orderly sequence of chemotherapy trials that serves as a model for cancer chemotherapy development. Recent studies have defined the least therapy required to minimize toxicity while maintaining a high cure rate in "low-risk" patients. Further improvements are necessary in "high-risk" patients; evaluation of new regimens by means of randomized trials is essential.